The objective response rate for LM was 51.6%, including a 15.6% complete response, and the disease control rate was 81.3% by BICR in the LM efficacy evaluable ... supporting its effective CNS ...

Abstract: In this article, a novel predictive torque and stator flux control (PTSF) method is proposed for N-segment three-phase permanent magnet synchronous motor (N*3-phase PMSM), which can ...

Mumbai’s underground Metro Line-3 took a big step forward with the opening of its Phase 2A on May 9, connecting Bandra-Kurla Complex (BKC) to Acharya Atre Chowk in Worli. The new stretch was ...

In order to expand the application of the PMSM in the field of high-power traction, a robust predictive torque control (R-PTC) strategy for the N-segment three-phase PMSM (N*3-phase PMSM) is proposed ...

The company's phase 3 Essence study tested the therapy in patients with moderate hypertriglyceridemia who have or are at risk for atherosclerotic cardiovascular disease (ASCVD ...

Residents of J.P. Nagar have raised serious concerns about the proposed double-decker flyover under Namma Metro Phase 3, warning that its alignment could worsen traffic congestion near the already ...

Overall survival by IDH2 mutant allele (R140 or R172) in patients with late-stage mutant-IDH2 relapsed or refractory acute myeloid leukemia treated with enasidenib or conventional care regimens in the ...

Dive into Sprunki MSI Canon Phase 3, where new characters and immersive soundscapes deepen the narrative. Experience a thrilling evolution of dark themes. Sprunki MSI Phase 3 represents a thrilling ...

Merck, known as MSD outside of the United States and Canada, announced that the phase 3 KEYNOTE-B96 trial, also known as ENGOT-ov65, met its primary endpoint of progression-free survival (PFS) for the ...

BioMarin has followed through on its shift to external innovation, inking a deal to buy Inozyme for $270 million to add a phase 3 enzyme replacement therapy to its pipeline. California-based ...

But with promising early results from a phase 3 study in certain patients, the checkpoint inhibitor may have found its place. At a pre-specified interim analysis of Merck’s phase 3 Keynote-B96 ...

In 2024, Merck announced the initiation of the Phase 2/3 REJOICE-Ovarian01 trial evaluating raludotatug deruxtecan (R-DXd), an investigational potential first-in-class CDH6 directed DXd antibody ...